Boston Scientific (BSX) Q2 FY26 earnings call

Boston Scientific delivered solid Q2 FY26 results, exceeding EPS guidance due to tax benefits and meeting organic revenue targets. However, the company significantly lowered its full-year guidance for both revenue and EPS, primarily driven by unexpected slowdowns in the WATCHMAN and U.S. Electrophysiology markets. Management announced a restructuring program aimed at $500 million in run-rate savings by 2029 to reinvest in growth drivers and return to strong EPS growth by 2028, acknowledging a challenging 2027.